AWA
RETA

Aaron Wealth Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Aaron Wealth Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,774
Closed -$251K – 166
2021
Q2 		$251K Buy
+1,774
New +$200K 0.08% 138
2021
Q1 		– Sell
-1,774
Closed -$219K – 171
2020
Q4 		$219K Buy
+1,774
New +$233K 0.08% 122

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Aaron Wealth Advisors's RETA Position: Q3 2021 in Review

Aaron Wealth Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 1,774 shares — an estimated $251K sold.

Aaron Wealth Advisors first reported a position in RETA in Q4 2020 and held it in 2 quarters. The position peaked at $251K in Q2 2021. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

  • Aaron Wealth Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
  • Aaron Wealth Advisors sold 1,774 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $251K.
  • Aaron Wealth Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 2 quarters.
  • Aaron Wealth Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $251K in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on Aaron Wealth Advisors's 13F filing for Q3 2021, filed 21 Oct 2021.